Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial

• Published in: Annals of the rheumatic diseases Vol. 83; no. 5; pp. 651 - 660
• Main Authors: Peng, Linyi, Nie, Yuxue, Zhou, Jiaxin, Wu, Lijun, Chen, Xiaomei, Wang, Fang, Li, Jieqiong, Peng, Yu, Lu, Hui, Zhao, Lidan, Li, Mengtao, Zhao, Yan, Zeng, Xiaofeng, Fei, Yunyun, Zhang, Wen
• Format: Journal Article
• Language: English
• Published: United States BMJ Publishing Group Ltd and European League Against Rheumatism 01.05.2024; Elsevier Limited
• Subjects: Disease; Glucocorticoids; Glucocorticoids - therapeutic use; Humans; IgG4 related disease; Immune System Diseases; Immunoglobulin G; Immunoglobulin G4-Related Disease - drug therapy; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Patients; Recurrence; Remission Induction; Rheumatology; Steroid hormones; Therapeutics; Treatment Outcome; Glucocorticoids; Immune System Diseases; Therapeutics

ObjectivesIgG4-related disease (IgG4-RD) is an immune-mediated, fibroinflammatory disease. Induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy for maintenance treatment a challenge. The WInS IgG4-RD (withdraw immunosuppressants (IMs) and...